期刊
NEUROLOGY
卷 78, 期 5, 页码 309-314出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31824528c9
关键词
-
资金
- Biogen Idec
- Merck Serono,
- Novartis
- Associazione Amici del Centro Studi SM
- sanofi-aventis
- Bayer Schering Pharma
- Merck Serono
- Almirall
- Teva Pharmaceutical Industries Ltd
- Italian MS Society
Objective: To evaluate cognitive changes in a cohort of radiologically isolated syndromes (RIS) suggestive of multiple sclerosis (MS) and to assess their relationship with quantitative magnetic resonance (MR) measures such as white matter (WM), lesion loads, and cerebral atrophy. Methods: We assessed the cognitive performance in a group of 29 subjects with RIS recruited from 5 Italian MS centers and in a group of 26 patients with relapsing-remitting MS (RRMS). A subgroup of 19 subjects with RIS, 26 patients with RRMS, and 21 healthy control (HC) subjects also underwent quantitative MR assessments, which included WM T1 and T2 lesion volumes and global and cortical brain volumes. Results: Cognitive impairment of the same profile as that of RRMS was found in 27.6% of our subjects with RIS. OnMRscans, we found comparable levels of lesion loads and brain atrophy in subjects with RIS and well-established RRMS. In subjects with RIS, high T1 lesion volume (rho = 0.526, p = 0.025) and low cortical volume (rho = 0.481, p = 0.043) were associated with worse cognitive performance. Conclusions: These findings emphasize the importance of including accurate neuropsychological testing and quantitative MR metrics in subjects with RIS suggestive of MS. They can provide a better characterization of these asymptomatic subjects, potentially useful for diagnostic and therapeutic decisions. Neurology (R) 2012; 78:309-314
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据